Complications after Totally Implantable Venous Port Catheter Intervention in Cancer Patients

Reyhanoglu Hasan, Ozcan Kaan
{"title":"Complications after Totally Implantable Venous Port Catheter Intervention in Cancer Patients","authors":"Reyhanoglu Hasan, Ozcan Kaan","doi":"10.23937/2378-3397/1410134","DOIUrl":null,"url":null,"abstract":"Background: The aim of this study was to evaluate the complications associated with totally implantable venous port catheter interventions and the management of these complications. Methods: Between January 2011 and October 2020, we reviewed patients who had totally implantable venous port catheter interventions. A total of 543 catheters were inserted into cancer patients via the subclavian, jugular, or femoral vein. Demographic data, venous access, primary diagnosis, catheter-related complications, catheter duration of stay, and reasons for catheter removal were retrospectively analyzed. Results: The mean age of the patients was 53.6 years, with the sample consisting of 304 (55.98%) females and 239 (44.02%) males. The first three cancer diagnoses were breast cancer (35.72%), colon cancer (31.67%), and stomach cancer (12.89%). In most patients (72.37%), the right subclavian vein was used as the intervention site. Complications occurred in 8.8% (48 patients) of the patients in the early (1.28%) or late periods (6.8%) after the procedure. Catheter-related infection was the most common complication, at 2.5%. Conclusion: Some complications may occur during the insertion and use of totally implantable venous port catheters, although they are convenient for use in the treatment of patients undergoing chemotherapy. Given their long-term use in these patients, most of whom have metastatic cancer and are on immunosuppressive therapy, a careful approach during surgery and chemotherapy will reduce potential complications.","PeriodicalId":326011,"journal":{"name":"International Journal of Surgery Research and Practice","volume":"82 2","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Surgery Research and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23937/2378-3397/1410134","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The aim of this study was to evaluate the complications associated with totally implantable venous port catheter interventions and the management of these complications. Methods: Between January 2011 and October 2020, we reviewed patients who had totally implantable venous port catheter interventions. A total of 543 catheters were inserted into cancer patients via the subclavian, jugular, or femoral vein. Demographic data, venous access, primary diagnosis, catheter-related complications, catheter duration of stay, and reasons for catheter removal were retrospectively analyzed. Results: The mean age of the patients was 53.6 years, with the sample consisting of 304 (55.98%) females and 239 (44.02%) males. The first three cancer diagnoses were breast cancer (35.72%), colon cancer (31.67%), and stomach cancer (12.89%). In most patients (72.37%), the right subclavian vein was used as the intervention site. Complications occurred in 8.8% (48 patients) of the patients in the early (1.28%) or late periods (6.8%) after the procedure. Catheter-related infection was the most common complication, at 2.5%. Conclusion: Some complications may occur during the insertion and use of totally implantable venous port catheters, although they are convenient for use in the treatment of patients undergoing chemotherapy. Given their long-term use in these patients, most of whom have metastatic cancer and are on immunosuppressive therapy, a careful approach during surgery and chemotherapy will reduce potential complications.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
全植入式静脉口导管介入治疗癌症的并发症
背景:本研究的目的是评估与全植入式静脉口导管介入相关的并发症和这些并发症的处理。方法:在2011年1月至2020年10月期间,我们回顾了采用完全植入式静脉端口导管介入治疗的患者。共有543根导管通过锁骨下静脉、颈静脉或股静脉插入癌症患者。回顾性分析人口学资料、静脉通路、初步诊断、导管相关并发症、导管停留时间和拔管原因。结果:患者平均年龄53.6岁,女性304例(55.98%),男性239例(44.02%)。诊断出的前三位癌症分别是乳腺癌(35.72%)、结肠癌(31.67%)和胃癌(12.89%)。大多数患者(72.37%)采用右锁骨下静脉作为介入部位。术后早期(1.28%)或后期(6.8%)出现并发症的患者占8.8%(48例)。导管相关感染是最常见的并发症,占2.5%。结论:全植入式静脉口导管在化疗患者中使用方便,但仍可能出现一些并发症。考虑到这些患者的长期使用,其中大多数患有转移性癌症并正在接受免疫抑制治疗,手术和化疗期间的谨慎方法将减少潜在的并发症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Clinical Expressions of Herniosis: Report of a Case Giant Hydronephrosis Presented as a Huge Abdominal Mass in a 22-Year-Old Male: A Case Report Minimally Invasive Surgery for Resection of Appendiceal Mucocele: A Single-Center Experience Case Series Postoperative Tetanus in Abdominal Surgery: Scope Review A General Surgeon's Guide to Post COVID-19 Multi-System Inflammatory Syndrome (MIS)
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1